Nafamostat – LTX-608
LTX-608: The other nafamostat opportunity with broad potential
Nafamostat is a unique molecule that has potential beyond Niyad
Disseminated intravascular coagulation (DIC)
Approved indication in Japan and South Korea; intellectual property protection will focus on method of use patents based on the complexity of DIC treatment
COVID treatment
Various ex-US studies have demonstrated positive results; publications support development as a potential COVID treatment by inhibiting TMPRSS2; A potent broad-spectrum serine protease inhibitor that blocks host protease activation of the viral spike protein 1
Lowell has a published patent regarding nafamostat antiviral for COVID and others
Acute respiratory distress syndrome (ARDS)
A life-threatening lung injury that allows fluid to leak into lungs; Nafamostat potential modes of action of anticoagulation, anti-inflammation and sustaining endothelial barrier function/preventing vascular leak could support exploring development
Acute pancreatitis
Approved indication in Japan and South Korea